Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials

Inger Johanne Zwicky Eide, Simone Stensgaard, Åslaug Helland, Simon Ekman, Anders Mellemgaard, Karin Holmskov Hansen, Saulius Cicenas, Jussi Koivunen, Bjørn Henning Grønberg, Boe Sandahl Sørensen, Odd Terje Brustugun